Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ville Koistinen, Paula Kauppi, Juhana Idänpään-Heikkilä, Lauri Veijalainen, Ilona Iso-Mustajärvi, Tero Ylisaukko-oja, Juha Mehtälä, Arja Viinanen & Maritta Kilpeläinen. (2022) Effectiveness of mepolizumab in patients with severe eosinophilic asthma: results from real-world clinical practice in Finland. Journal of Asthma 59:12, pages 2375-2385.
Read now
Read now
Elliot Israel,Giorgio Walter Canonica,Guy Brusselle,Shibing Yang,Peter H. Howarth,Amber L. Martin,Maria Koufopoulou,Steven G. Smith,Rafael Alfonso-Cristancho,. (2022) Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. Journal of Asthma 59:11, pages 2201-2217.
Read now
Read now
Jean-Pierre Llanos, Hector Ortega, Michael Bogart, Elizabeth R Packnett, Janna Manjelievskaia, Christopher F Bell & Beth Hahn. (2020) Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs. Journal of Asthma and Allergy 13, pages 77-87.
Read now
Read now
Peter Valentin Tomazic, Barbara Darnhofer & Ruth Birner-Gruenberger. (2020) Nasal mucus proteome and its involvement in allergic rhinitis. Expert Review of Proteomics 17:3, pages 191-199.
Read now
Read now
Marco Caminati, Diego Bagnasco, Rachele Vaia & Gianenrico Senna. (2019) New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic. Biologics: Targets and Therapy 13, pages 89-95.
Read now
Read now
Juan Carlos Murillo, Ves Dimov & Alexei Gonzalez-Estrada. (2018) An evaluation of fevipiprant for the treatment of asthma: a promising new therapy?. Expert Opinion on Pharmacotherapy 19:18, pages 2087-2093.
Read now
Read now
Corrado Pelaia, Alessandro Vatrella, Maria Teresa Busceti, Luca Gallelli, Rosa Terracciano, Rocco Savino & Girolamo Pelaia. (2017) Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Design, Development and Therapy 11, pages 3137-3144.
Read now
Read now
Articles from other publishers (32)
Jeremiah Hwee, Lynn Huynh, Shawn Du, Namhee Kwon, Rupert W. Jakes, Rafael Alfonso-Cristancho, Lee Baylis, Gema Requena, Anamika Khanal, Marc E. Rothenberg & Mei Sheng Duh. (2023) Hypereosinophilic syndrome in Europe: Retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization. Annals of Allergy, Asthma & Immunology 130:6, pages 768-775.
Crossref
Crossref
Hillary V. Schiff, Candy M. Rivas, William P. Pederson, Estevan Sandoval, Samuel Gillman, Joy Prisco, Moeno Kume, Gregory Dussor, Josef Vagner, Julie G. Ledford, Theodore J. Price, Kathryn A. DeFea & Scott Boitano. (2022) β‐Arrestin‐biased proteinase‐activated receptor‐2 antagonist C781 limits allergen‐induced airway hyperresponsiveness and inflammation. British Journal of Pharmacology 180:5, pages 667-680.
Crossref
Crossref
Wytske J. Fokkens, Joaquim Mullol, David Kennedy, Carl Philpott, Veronica Seccia, Robert C. Kern, André Coste, Ana R. Sousa, Peter H. Howarth, Victoria S. Benson, Bhabita Mayer, Steve W. Yancey, Robert Chan & Simon B. Gane. (2022)
Mepolizumab for chronic rhinosinusitis with nasal polyps (
SYNAPSE
): In‐depth sinus surgery analysis
. Allergy 78:3, pages 812-821.
Crossref
Crossref
Ian D. Pavord, Elisabeth H. Bel, Arnaud Bourdin, Robert Chan, Joseph K. Han, Oliver N. Keene, Mark C. Liu, Neil Martin, Alberto Papi, Florence Roufosse, Jonathan Steinfeld, Michael E. Wechsler & Steven W. Yancey. (2021) From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases. Allergy 77:3, pages 778-797.
Crossref
Crossref
Mark C. Liu, Elisabeth H. Bel, Oliver Kornmann, Wendy C. Moore, Norihiro Kaneko, Steven G. Smith, Neil Martin, Robert G. Price, Steven W. Yancey & Marc Humbert. (2022) Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET. ERJ Open Research 8:1, pages 00419-2021.
Crossref
Crossref
Gerald J. Gleich, Florence Roufosse, Geoffrey Chupp, Stanislas Faguer, Bastian Walz, Andreas Reiter, Steven W. Yancey, Jane H. Bentley, Jonathan Steinfeld, Gabriel Ricardo García, Pablo Pascale, Luis Wehbe, Daniël Blockmans, Florence Roufosse, Martti Anton Antila, Daniela Blanco, Andreia Luisa Francisco Pez, Stanislas Faguer, Jean-Emmanuel Kahn, Guillaume Lefévre, Antoine Neel, Peter M. Kern, Andreas J. Reiter, Bastian Walz, Tobias Welte, Fabrizio Pane, Alessandro M. Vannucchi, Ruth Cerino-Javier, Dante D. Hernández-Colín, Héctor Glenn Valdéz-López, Izabela R. Kupryś-Lipińska, Jacek Musial, Eniko Mihaly, Viola Maria Popov, Vladimir Ivanov, Nikolay Tsyba, Maria C. Cid, Maria Laura Fox, Guillermo Sanz Santillana, Andrew J. Wardlaw, Praveen Akuthota, Joseph H. Butterfield, Geoffrey L. Chupp, Gerald J. Gleich, Devi Jhaveri & Marc E. Rothenberg. (2021) Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study. The Journal of Allergy and Clinical Immunology: In Practice 9:12, pages 4431-4440.e1.
Crossref
Crossref
Jared Silver, Nestor Molfino, Michael Bogart, Elizabeth R. Packnett, Donna McMorrow, Juan Wu & Beth Hahn. (2021) Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis. Clinical Therapeutics 43:12, pages 2064-2073.
Crossref
Crossref
Junfeng Chen, Yi Xu, Jiang Wang & Guo Xin Mo. 2021. Sudden Death. Sudden Death
299
321
.
Fariza Mishaal Saiema Badloe, Shauni De Vriese, Katarina Coolens, Carsten B. Schmidt-Weber, Johannes Ring, Jan Gutermuth & Inge Kortekaas Krohn. (2020) IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis. Clinical and Translational Allergy 10:1.
Crossref
Crossref
Florence Roufosse, Jean-Emmanuel Kahn, Marc E. Rothenberg, Andrew J. Wardlaw, Amy D. Klion, Suyong Yun Kirby, Martyn J. Gilson, Jane H. Bentley, Eric S. Bradford, Steven W. Yancey, Jonathan Steinfeld & Gerald J. Gleich. (2020) Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology 146:6, pages 1397-1405.
Crossref
Crossref
Tim Harrison, Giorgio Walter Canonica, Geoffrey Chupp, Jason Lee, Florence Schleich, Tobias Welte, Antonio Valero, Kim Gemzoe, Aoife Maxwell, Sandra Joksaite, Shibing Yang, Peter Howarth & Melissa K. Van Dyke. (2020) Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. European Respiratory Journal 56:4, pages 2000151.
Crossref
Crossref
Vivian Aranez & Julian AmbrusJrJr. (2019) Immunologic Adverse Effects of Biologics for the Treatment of Atopy. Clinical Reviews in Allergy & Immunology 59:2, pages 220-230.
Crossref
Crossref
Ian D. Pavord, Eugene R. Bleecker, Roland Buhl, Pascal Chanez, Elisabeth H. Bel, Peter Howarth, Daniel J. Bratton, Frank C. Albers & Steven Yancey. (2020) Response to mepolizumab treatment is sustained across 4-weekly dosing periods. ERJ Open Research 6:3, pages 00068-2020.
Crossref
Crossref
Camille Taillé, Pascal Chanez, Gilles Devouassoux, Alain Didier, Christophe Pison, Gilles Garcia, Jeremy Charriot, Stéphane Bouée, Alina Gruber, Celine Pribil, Arnaud Bourdin & Marc Humbert. (2020) Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. European Respiratory Journal 55:6, pages 1902345.
Crossref
Crossref
Shaila Shabbir, Isabelle J. Pouliquen, Jane H. Bentley, Eric S. Bradford, Morrys C. Kaisermann & Muna Albayaty. (2020) The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial. Clinical Pharmacology in Drug Development 9:3, pages 375-385.
Crossref
Crossref
Alejandra Méndez Sánchez, Jose Ramón Gutiérrez Martínez, Andrés Coca Pelaz & Maria Antonia Vázquez Piñera. (2019) Enfermedad respiratoria relacionada con aspirina tratada con mepolizumab en un paciente pediátrico. Archivos de Bronconeumología 55:1, pages 55-57.
Crossref
Crossref
Alejandra Méndez Sánchez, Jose Ramón Gutiérrez Martínez, Andrés Coca Pelaz & Maria Antonia Vázquez Piñera. (2019) Aspirin-Exacerbated Respiratory Disease in a Pediatric Patient Treated with Mepolizumab. Archivos de Bronconeumología (English Edition) 55:1, pages 55-57.
Crossref
Crossref
Heather Ellen Hoch, William Carl AndersonIIIIII & Stanley James Szefler. 2019. Kendig's Disorders of the Respiratory Tract in Children. Kendig's Disorders of the Respiratory Tract in Children
747
755.e3
.
K.L. Winthrop, X. Mariette, J.T. Silva, E. Benamu, L.H. Calabrese, A. Dumusc, J.S. Smolen, J.M. Aguado & M. Fernández-Ruiz. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clinical Microbiology and Infection 24, pages S21-S40.
Crossref
Crossref
Pulla Reddy Boggu, Jungsuk Cho, Youngsoo Kim & Sang-Hun Jung. (2018) Identification of novel 2-benzyl-1-indanone analogs as interleukin-5 inhibitors. European Journal of Medicinal Chemistry 152, pages 65-75.
Crossref
Crossref
Alvise Berti, Ulrich Specks, Karina A. Keogh & Divi Cornec. (2017) Current and Future Treatment Options for Eosinophilic Granulomatosis With Polyangiitis. Current Treatment Options in Rheumatology 3:4, pages 193-206.
Crossref
Crossref
Pulla Reddy Boggu, Eeda Venkateswararao, Manoj Manickam, Youngsoo Kim & Sang-Hun Jung. (2017) Discovery of novel 3-(hydroxyalkoxy)-2-alkylchromen-4-one analogs as interleukin-5 inhibitors. European Journal of Medicinal Chemistry 139, pages 290-304.
Crossref
Crossref
Diego Bagnasco, Matteo Ferrando, Gilda Varricchi, Francesca Puggioni, Giovanni Passalacqua & Giorgio Walter Canonica. (2017) Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. Frontiers in Medicine 4.
Crossref
Crossref
Inmaculada Doña, María Salas, Esther Barrionuevo & Paloma Campo. (2017) Management of Respiratory Symptoms Induced by Non-Steroidal Anti-Inflammatory Drugs. Current Treatment Options in Allergy 4:2, pages 268-282.
Crossref
Crossref
Lisa M. Sedger, Charani Ranasinghe, Michael F. McDermott & Parisa Asvadi. 2017. Immunotherapy - Myths, Reality, Ideas, Future. Immunotherapy - Myths, Reality, Ideas, Future.
Emine Güven Sakalar, Nuray Bayar Muluk, Murat Kar & Cemal Cingi. (2016) Aspirin-exacerbated respiratory disease and current treatment modalities. European Archives of Oto-Rhino-Laryngology 274:3, pages 1291-1300.
Crossref
Crossref
Dimitrios Terzakis & Christos Georgalas. (2017) Polyps, asthma, and allergy: what's new. Current Opinion in Otolaryngology & Head & Neck Surgery 25:1, pages 12-18.
Crossref
Crossref
Roopesh Singh Gangwar, Nadine Landolina, Ludovica Arpinati & Francesca Levi-Schaffer. (2017) Mast cell and eosinophil surface receptors as targets for anti-allergic therapy. Pharmacology & Therapeutics 170, pages 37-63.
Crossref
Crossref
Divi Cornec, Emilie Cornec-Le Gall & Ulrich Specks. (2017) Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn. Nephrology Dialysis Transplantation, pages gfw384.
Crossref
Crossref
Girolamo Pelaia, Alessandro Vatrella & Rosario MaselliGirolamo Pelaia, Alessandro Vatrella & Rosario Maselli. 2017. Asthma: Targeted Biological Therapies. Asthma: Targeted Biological Therapies
51
66
.
Bhavisha PatelJoseph H. ButterfieldCatherine R. WeilerSunanda V. Kane. (2016) Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 35:6, pages 300-303.
Crossref
Crossref
Sean S. Liour, Andrew Tom, Yueh-Hsuan Chan & Tse Wen Chang. (2016) Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody. Pediatric Allergy and Immunology 27:5, pages 446-451.
Crossref
Crossref